Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Why it matters: Amgen's performance in 2024 was in line with our estimates, but 2025 guidance is ahead of our prior outlook, largely due to biosimilar denosumab competition (bone drug Prolia and ...

Despite headwinds from biosimilar and branded competition, Amgen's newer blockbusters like cholesterol-lowering drug Repatha defend its wide moat and keep free cash flow above 30% of sales in our ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a complex landscape of opportunities and challenges as it positions itself ...

The appeal court set Empire Company Limited et al v. Attorney General of Canada, A-192-24 on Feb. 12, Wednesday. This appeal ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

The company's development of MariTide positions it to compete in this lucrative space, but it faces stiff competition from established players and other new entrants. Amgen's established products ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

These products underscore Amgen's capacity to seize growth opportunities, particularly in rare disease markets. Additionally, ...